ANGLE Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Andrew David Newland

Directeur général

UK£281.0k

Rémunération totale

Pourcentage du salaire du PDG	95.7%
Durée du mandat du directeur général	20.7yrs
Propriété du PDG	2.3%
Durée moyenne d'occupation des postes de direction	1.8yrs
Durée moyenne du mandat des membres du conseil d'administration	9.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Andrew David Newland a-t-elle évolué par rapport aux bénéfices de ANGLE?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-UK£18m
Mar 31 2024	n/a	n/a	-UK£19m
Dec 31 2023	UK£281k	UK£269k	-UK£20m
Sep 30 2023	n/a	n/a	-UK£21m
Jun 30 2023	n/a	n/a	-UK£22m
Mar 31 2023	n/a	n/a	-UK£22m
Dec 31 2022	UK£264k	UK£253k	-UK£22m
Sep 30 2022	n/a	n/a	-UK£19m
Jun 30 2022	n/a	n/a	-UK£17m
Mar 31 2022	n/a	n/a	-UK£16m
Dec 31 2021	UK£446k	UK£242k	-UK£15m
Sep 30 2021	n/a	n/a	-UK£15m
Jun 30 2021	n/a	n/a	-UK£16m
Mar 31 2021	n/a	n/a	-UK£14m
Dec 31 2020	UK£392k	UK£240k	-UK£12m
Jun 30 2020	n/a	n/a	-UK£10m
Mar 31 2020	n/a	n/a	-UK£11m
Dec 31 2019	UK£244k	UK£160k	-UK£11m
Oct 31 2019	n/a	n/a	-UK£10m
Jul 31 2019	n/a	n/a	-UK£9m
Apr 30 2019	n/a	n/a	-UK£9m
Jan 31 2019	n/a	n/a	-UK£9m
Oct 31 2018	n/a	n/a	-UK£8m
Jul 31 2018	n/a	n/a	-UK£8m
Apr 30 2018	UK£336k	UK£229k	-UK£8m

Rémunération vs marché: La rémunération totale de Andrew David ($USD 351.68K ) est dans la moyenne des entreprises de taille similaire sur le marché UK ($USD 354.03K ).

Rémunération et revenus: La rémunération de Andrew David a augmenté alors que l'entreprise n'est pas rentable.

PDG

Andrew David Newland (63 yo)

20.7yrs

Titularisation

UK£281,000

Compensation

Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Andrew David Newland	Founder	no data	UK£281.00k	2.26% £ 767.0k
Ian Griffiths	CFO, Finance Director	7.4yrs	UK£180.00k	0.39% £ 133.5k
Martin Cooke	Director of Operations & Regulatory Affairs	6.8yrs	pas de données	pas de données
Karen Miller	Chief Scientific Officer	1.8yrs	pas de données	pas de données
Andrew Holder	Head of Investor Relations	no data	pas de données	pas de données
Anne-Sophie Pailhes-Jimenez	Head of R&D and Senior Director	1.1yrs	pas de données	pas de données
Brett Swansiger	Chief Commercial Officer	1.8yrs	pas de données	pas de données

1.8yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: L'équipe de direction de AGL n'est pas considérée comme expérimentée (ancienneté moyenne 1.8 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Andrew David Newland	Founder	20.7yrs	UK£281.00k	2.26% £ 767.0k
Ian Griffiths	CFO, Finance Director	20.7yrs	UK£180.00k	0.39% £ 133.5k
Harold Swerdlow	Member of Scientific Advisory Board	no data	pas de données	pas de données
Juliet Thompson	Non-Executive Director	1.8yrs	UK£48.00k	pas de données
Ashok Venkitaraman	Member of Scientific Advisory Board	no data	pas de données	pas de données
Brian Howlett	Non-Executive & Senior Independent Director	11.8yrs	UK£27.00k	0.0031% £ 1.0k
Jan Groen	Independent Non-Executive Chairman	6yrs	UK£50.00k	pas de données
Clive Stanway	Member of Scientific Advisory Board	no data	pas de données	pas de données
Adrian Newland	Member of Scientific Advisory Board	no data	pas de données	pas de données
James Reuben	Member of Scientific Advisory Board	9.4yrs	pas de données	pas de données
Daniel Danila	Member of Scientific Advisory Board	9.3yrs	pas de données	pas de données
Greg Shaw	Member of Scientific Advisory Board	no data	pas de données	pas de données

9.4yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AGL sont considérés comme expérimentés (ancienneté moyenne 9.4 ans).

ANGLE Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

ANGLE plc, Annual General Meeting, Jun 26, 2024

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

Recent updates

Angle plc Announces Parsortix Based PD-L1 Assay Showcased at AACR

New major risk - Share price stability

Angle plc PLC Announces Parsortix enriched CTC & ctDNA in NSCLC Patients

First half 2024 earnings released: UK£0.029 loss per share (vs UK£0.038 loss in 1H 2023)

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

New minor risk - Financial data availability

ANGLE plc to Report First Half, 2024 Results on Sep 26, 2024

Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System

New minor risk - Shareholder dilution

Full year 2023 earnings released: UK£0.077 loss per share (vs UK£0.088 loss in FY 2022)

ANGLE plc Provides Revenue Guidance for the First Half of 2024

ANGLE plc to Report Q4, 2023 Results on Jun 07, 2024

ANGLE plc Announces Publication of Study Using the Parsortix System

ANGLE plc, Annual General Meeting, Jun 26, 2024

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.039 loss in 1H 2022)

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

Price target decreased by 35% to UK£0.94

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

First half 2022 earnings: EPS and revenues miss analyst expectations

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Price target increased to UK£2.16

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target increased to UK£1.85

Insufficient new directors

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

Price target increased to UK£1.80

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

Insufficient new directors

First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020)

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

CFO, Finance Director exercised options to buy UK£524k worth of stock.

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Founder exercised options and sold UK£1.0m worth of stock

Forecast to breakeven in 2025

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer